Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma (Q37163867)

18 August 2017

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma (English)

1 reference

18 August 2017

0 references

1 reference

10

Hagop M Kantarjian

1 reference

18 August 2017

5

William G Wierda

1 reference

18 August 2017

4

Susan O'Brien

1 reference

18 August 2017

11

Michael J Keating

1 reference

18 August 2017

6

Susan Lerner

1 reference

18 August 2017

Apostolia Maria Tsimberidou

series ordinal

1

object named as

Apostolia-Maria Tsimberidou

1 reference

18 August 2017

3

Peter McLaughlin

1 reference

18 August 2017

2

Sijin Wen

1 reference

18 August 2017

7

Sara Strom

1 reference

18 August 2017

Emil J Freireich

8

1 reference

18 August 2017

L Jeffrey Medeiros

series ordinal

9

1 reference

18 August 2017

language of work or name

English

0 references

publication date

29 December 2008

1 reference

Journal of Clinical Oncology

18 August 2017

1 reference

18 August 2017

27

1 reference

18 August 2017

6

1 reference

18 August 2017

904-910

1 reference

Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Subsequent Neoplasia in Chronic Lymphocytic Leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Second cancers in patients with chronic lymphocytic leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Richter's syndrome--the downside of fludarabine?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979239

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19114699

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19114699

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19114699

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.17.5398

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19114699

1 reference